If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 181 - 190 of 282
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Objective
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Protocol No
C4THERAPEUTICS-CFT7455-1101
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
Objective
Study of iadademstat and gilteritinib in patients with R/R AML with FMS-like T/K mutation
Protocol No
ORYZON-CL04-ORY-1001
Categories
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
Objective
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Categories
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
Objective
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Protocol No
JNJ-75276617ALE1001
Phase 1/1b, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) a
Objective
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL B-cell
Protocol No
PRECISION-PBCAR0191-01
Categories
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients with Vestibular Schwannomas
Objective
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas (VS PREHAB)
Protocol No
IIT-HARRIS-PREHAB-VS
Categories
Hand Function as a Biomarker of Brain Tumor Motor Cortical Involvement
Objective
Hand Function in Brain Tumors
Protocol No
IIT-KRUCOFF-HAND-FUNCTION
Categories
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
Objective
A Phase I/II Trial of Venetoclax + Dexamethasone in R/R Systemic Light-Chain Amyloidosis
Protocol No
COLUMBIAUNIVERSITY-AAAT8639
Categories
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Objective
Comparing drugs for advanced non-small cell lung cancer with EGFR and MET gene changes
Protocol No
SWOG-S1900G
Categories